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Background: 
Preeclampsia	is	a	hypertensive	disorder	of	pregnancy	affec6ng	mul6ple	
organ	systems	complica6ng	2-8%	of	pregnancies.	It	is	defined	as	new-
onset	hypertension	and	proteinuria,	or	hypertension	and	significant	
end-organ	dysfunc6on,	typically	presen6ng	aAer	20	weeks	of	
gesta6on.			
	
It	is	caused	by	placental	and	maternal	vascular	dysfunc6on	and	
resolves	with	delivery	of	the	fetus,	which	causes	complica6ons	to	the	
fetus	depending	on	the	gesta6onal	age	at	the	6me	of	delivery.		It	is	
considered	a	heterogeneous	disorder,	meaning	the	mechanism	leading	
to	the	development	of	the	disease	can	differ	in	women	with	various	
risk	factors.	Maternal	risk	factors	include:	past	history	of	preeclampsia,	
chronic	hypertension,	pregesta6onal	diabetes,	mul6fetal	gesta6on,	
chronic	kidney	disease,	assisted	reproduc6ve	technologies,	and	some	
autoimmune	diseases.			
	
The	exact	pathophysiology	of	preeclampsia	remains	unknown	but	it	is	
suggested	to	involve	both	maternal	and	fetal/placental	factors.	
Biophysical	measurements	to	aid	in	the	early	detec6on	of	
preeclampsia	include	mean	arterial	pressure	(MAP)	and	uterine	artery	
Doppler	analysis.	Several	biomarkers	have	been	studied	for	their	
effec6veness	in	predic6ng	preeclampsia.	Combining	maternal	risk	
factors	with	biomarker	measurements	taken	in	the	first	trimester	could	
allow	for	early	detec6on	of	preeclampsia	and	ini6a6on	of	low-dose	
aspirin	to	improve	maternal	and	fetal	outcomes.		 
 
 
 
 
 
 
 
 
 
 
  
Methods:  
A	computerized	search	of	literature	was	conducted	using	PubMed	and	
Cumula6ve	Index	to	Nursing	and	Health	Literature	(CINAHL).	The	search	terms	
were	as	follows:	preeclampsia,	risk	factors,	biomarkers,	aspirin	
	
Inclusion	criteria:	Peer-reviewed	ar6cles	over	the	last	10	years	with	a	nursing	or	
medical	focus	on	maternal	factors,	biophysical	measurements,	biochemical	
markers,	or	a	combina6on	of	the	three,	detected	in	the	first	trimester	of	
pregnancy	leading	to	the	development	of	preecalmpsia	were	included.	
	
Exclusion	criteria:	Ar6cles	focusing	on	the	detec6on	of	preeclampsia	in	the	
second	or	third	trimester,	mul6gesta6on	pregnancies,	or	prophylac6c	
medica6on	other	than	aspirin	were	excluded.		
Results & Discussion: 
The	blueprint	for	preeclampsia	occurs	early	in	gesta6on,	
weeks	to	months	prior	to	the	onset	of	clinical	
manifesta6ons	of	hypertension	and	proteinuria.		
Developing	a	screening	protocol	has	been	the	focus	of	
recent	research	and	suggests	that	a	mul6parametric	test	
improves	early	detec6on	rates.		Maternal	risk	factors,	
biophysical	measurements,	and	biochemical	markers	by	
themselves	are	not	sensi6ve	enough	to	predict	
preeclampsia.		A	combina6on	of	the	three,	detected	in	the	
first	trimester,	increases	the	sensi6vity	and	posi6ve	
predic6ve	value,	allowing	for	ini6a6ng	of	aspirin	
prophylaxis	in	deemed	high-risk	pa6ents	to	be	
implemented.			
	
Research	suggests	that	a	first	trimester	screening	including	
mean	arterial	pressure	(MAP),	uterine	artery	resistance,	
PAPP-A	and	placental	growth	factor	(PlGF)	can	detect	96%	
of	early	onset	pre-eclampsia.	A	mul6-parameter	screening	
tool	would	help	increase	detec6on	rates,	especially	in	
nulliparous	women	where	maternal	history	and	risk	
factors	alone	are	insufficient	screening	tools.		A	first	
trimester	screening	tool	would	allow	for	the	early	
detec6on	of	preeclampsia	and	ini6a6on	of	prophylac6c	
low-dose	aspirin	treatment.		It	is	recommended	that	low	
dose	aspirin	should	be	started	in	high-risk	women	prior	to	
16	weeks	of	gesta6on.		
 
Research Questions: 
1. What	maternal	risk	factors,	biophysical	measurements,	and	biochemical	
markers	are	associated	with	preeclampsia?	
2.	What	factors	in	combina;ons	can	be	used	to	predict	preeclmapsia	in	the	
first	trimester?	
3.	Can	aspirin	given	prior	to	16	weeks	gesta;on	prevent	preeclampsia	in	high-
risk	women?	
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Problem Statement:  
Preeclampsia	is	a	significant	cause	of	maternal	and	fetal	mortality	and	
morbidity,	causing	9-26%	of	maternal	deaths	and	15%	of	preterm	
births.	In	addi6on,	women	with	a	history	of	preeclampsia	are	at	
increased	risk	for	future	cardiovascular	and	renal	disease.		Even	with	
known	associated	risk	factors	and	maternal	biomarkers	there	is	
currently	no	defini6ve	screening	test	to	use	for	the	predic6on	of	
preeclampsia.	Maternal	risk	factors	alone	cannot	effec6vely	predict	
preeclampsia,	especially	in	low-risk	women.		
Nursing Practice Implications: 
Nursing	prac6ce	should	focus	on	performing	a		
comprehensive	maternal	history	and	obtaining	accurate	
biophysical	measurements.		Accurate	assessment	of	blood	
pressure	should	be	obtained	aAer	five	minutes	of	rest,	
with	the	pa6ent	si^ng	with	feed	on	the	ground	with	legs	
uncrossed.	High-risk	women	should	be	started	on	
prophylaxis	aspirin	for	the	preven6on	of	preeclampsia.		
Nurses	need	to	be	knowledgeable	on	the	risk	factors	of	
preeclmapsia	and	also	the	clinical	presenta6on	so	
maternal	and	fetal	assessment	can	be	closely	monitored.	
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